Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis.
Thermo Fisher Scientific (NYSE:TMO), meanwhile, delivered another quarter suggesting that the long-awaited recovery in life sciences spending is gaining traction, supported by improving demand across pharmaceutical and biotechnology customers.
The question for investors is now whether Abbott’s (NYSE:ABT) diversified healthcare portfolio or Thermo Fisher’s (NYSE:TMO) exposure to a recovering life sciences market offers the stronger long-term opportunity.
Bull Case
One of the biggest highlights of the quarter for Abbott Laboratories (NYSE:ABT) was its diagnostics segment. The company’s cancer diagnostics business, which was recently integrated through the Exact Sciences acquisition, is benefiting from an expanding base that comprises both new and repeat users of the colorectal cancer screening test, Cologuard. Sales in its diagnostics segment rose 42% to $3.09 billion in fiscal Q2, surpassing the estimate of $3.02 billion, emerging as one of the company’s strongest performers during the quarter.
Analysts agree with this sentiment. William Blair believes the quarter should improve investor confidence in Abbott’s (NYSE:ABT) Exact Sciences acquisition. The firm noted that stronger cancer diagnostics growth and resilient medical device demand helped ease concerns surrounding procedure volumes and broader medtech end markets.
The firm also pointed to improving trends in Abbott’s (NYSE:ABT) nutrition business and expects upcoming product launches to provide additional support during the second half of 2026 and into fiscal 2027.
While Abbott’s (NYSE:ABT) strength came from the breadth of its healthcare portfolio, Thermo Fisher’s (NYSE:TMO) investment case increasingly depends on whether life sciences spending is finally emerging from its post-pandemic slowdown. Thermo Fisher Scientific Inc.’s (NYSE:TMO) quarter suggests that the recovery in life sciences spending is becoming increasingly broad-based. Management highlighted improving customer activity across pharmaceutical and biotechnology markets, while multiple operating segments returned to healthy growth. That is an important distinction because broader participation across business segments suggests customer spending is becoming healthier rather than merely stabilizing in one niche.
Thermo Fisher Scientific Inc.’s (NYSE:TMO) Life Sciences Solutions segment reinforced the recovery narrative. Reported revenue climbed 13% year over year, while organic revenue rose 3%, led by continued strength in the high-margin bioproduction business. Healthy demand in this segment is particularly encouraging because it reflects ongoing investments and supports management’s view that end-market conditions continue to improve.
Perhaps the biggest positive from the quarter was the recovery in Analytical Instruments, a business that had faced weak demand for nearly two years as biotechnology funding slowed. Its return to growth provides another indication that laboratory spending is beginning to normalize. While one quarter does not establish a trend, sustained improvement in this segment would strengthen the case that the industry’s post-pandemic downturn is easing.
Thermo Fisher Scientific Inc. (NYSE:TMO) also continued investing in product innovation through launches such as the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers. Continued innovation is particularly important in analytical instruments, where technological leadership often supports premium pricing and high customer switching costs.
Bear Case
Abbott Laboratories’ (NYSE:ABT) optimistic second-half outlook still depends on execution. Management has expressed confidence that sales and earnings growth will accelerate in the second half of 2026. While this outlook is supported by improving momentum across multiple business segments, investors will need to see that acceleration materialize over the coming quarters. Notably, Abbott Laboratories (NYSE:ABT) reaffirmed rather than raised its full-year comparable sales growth guidance of 6.5% to 7.5%, suggesting that management remains prudent despite its strong second-quarter performance.
In Thermo Fisher’s (NYSE:TMO) case, the biggest risk is that investors extrapolate one strong quarter into a full industry recovery. Organic revenue increased 5%, representing meaningful progress but still remaining below the double-digit growth rates the company previously achieved. As a result, expectations for a rapid return to historic growth may prove optimistic. The company’s recovery also remains heavily dependent on pharmaceutical and biotechnology spending. If customers once again delay capital investment, today’s improving demand environment could prove less durable than the market currently expects.
The latest earnings have also raised expectations considerably. Following management’s guidance increase, investors now expect Thermo Fisher Scientific (NYSE:TMO) to continue expanding margins while delivering stronger organic growth. With the shares already trading at a premium valuation, future upside may increasingly depend on execution rather than simply improving industry conditions.
Institutional investors remain constructive on both companies. According to Insider Monkey’s database of 1,022 hedge funds, Abbott’s (NYSE:ABT) hedge fund ownership increased from 71 funds at the end of Q4 2025 to 73 funds in Q1 2026. Thermo Fisher (NYSE:TMO) also saw modest improvement, with hedge fund ownership rising from 113 to 115 funds over the same period. Although neither change is dramatic, the steady increase suggests professional investors continue viewing both companies as attractive long-term healthcare holdings.
Conclusion
Both companies delivered encouraging quarters, but they are benefiting from very different drivers. Abbott’s (NYSE:ABT) strength comes from diversification, with diagnostics, medical devices, and nutrition all contributing to growth, and reducing the company’s reliance on any single business. Thermo Fisher (NYSE:TMO), by contrast, is more closely tied to the recovery in pharmaceutical and biotechnology spending. If that recovery continues broadening, Thermo Fisher (NYSE:TMO) may have greater operating leverage. However, if end-market conditions soften again, Abbott’s (NYSE:ABT) diversified portfolio could prove more resilient.
While we acknowledge the risk and potential of TMO and ABT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TMO and ABT and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.
Disclosure: None. Follow Insider Monkey on Google News.
